← Back to Search

Ianalumab for Lupus (SIRIUS-SLE LTE Trial)

Phase 3
Recruiting
Research Sponsored by Novartis Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Participants must have participated in either one of the two SIRIUS-SLE core studies, CVAY736F12301 or CVAY736F12302, and have completed the treatment period through Week 60 without treatment discontinuation.
Must not have
Women of child-bearing potential who refuse or are unable to use highly effective methods of contraception while on study treatment and for 6 months after stopping the study drug (or longer if required by concomitant medications)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, up to approximately 91 months
Awards & highlights

Summary

"This trial aims to assess the safety and tolerability of ianalumab over a long period in individuals with lupus who have finished treatment in one of two previous studies."

Who is the study for?
This trial is for people with systemic lupus erythematosus who finished a previous SIRIUS-SLE study without stopping treatment. They must consent to participate and, if under 18, have guardian consent plus their own assent. Participants should be expected to benefit from continued treatment.
What is being tested?
The trial is testing the long-term safety of Ianalumab in individuals with lupus who completed prior SIRIUS-SLE studies. It compares ongoing Ianalumab use against a placebo to see how well patients tolerate it over an extended period.
What are the potential side effects?
While specific side effects are not listed here, generally, drugs like Ianalumab may cause immune system changes leading to infections or allergic reactions and could affect blood counts or liver function.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I completed one of the SIRIUS-SLE studies without stopping the treatment.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am a woman able to have children and agree to use effective birth control during and 6 months after the study.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, up to approximately 91 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, up to approximately 91 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of treatment-emergent Adverse events/Serious Adverse events
Secondary outcome measures
Annualized BILAG moderate or severe flare rate
Average daily dose of oral corticosteroids administered
Change in Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index
+1 more

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: Ianalumab quarterlyExperimental Treatment1 Intervention
Ianalumab s.c. quarterly
Group II: Ianalumab monthlyExperimental Treatment1 Intervention
Ianalumab s.c. monthly
Group III: Placebo monthlyPlacebo Group1 Intervention
Placebo s.c. monthly

Find a Location

Who is running the clinical trial?

Novartis PharmaceuticalsLead Sponsor
2,889 Previous Clinical Trials
4,201,454 Total Patients Enrolled
~367 spots leftby Dec 2029
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top